ACRV vs TLRY · $65.1M cap vs rev $915.5M
Acrivon Therapeutics, Inc. Common Stock (ACRV) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
ACRV does not have a complete income-statement cache yet.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
ACRV currently screens at market cap $65.1M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the ACRV and TLRY stock pages for the full models.
Not investment advice.